RxDoctor Payments Data

Dana Dudley, NP

Family · Aiken, SCNPI 1205410230

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $14,771 of the $17,736 with a category attached, or 83.3%. It is spread thinly across 60 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,736in general payments, 2019–2025

Across 769 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • AstraZeneca$1K
  • Merck$1K
  • Johnson & Johnson$875
  • Daiichi Sankyo Inc.$842
  • Pfizer$809
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$14,77183%
  • Education$8525%
  • Other$2,11312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis87$3,394
AstraZeneca(2 entities)67$1,360
Merck54$1,127
Johnson & Johnson43$875
Daiichi Sankyo Inc.41$842
Pfizer41$809
Seagen Inc.25$765
Bayer19$459
Amgen23$445
Bristol Myers Squibb22$399
E.r. Squibb & Sons, L.L.C.25$395
Lilly USA, LLC17$342
Genentech USA, Inc.15$302
Exelixis Inc.10$300
Eisai Inc.11$265
Regeneron Healthcare Solutions, Inc.12$254
Taiho Oncology, Inc.11$246
Incyte Corporation13$244
AbbVie13$229
Coherus Oncology, Inc.7$216
Sobi, Inc8$211
Ipsen Biopharmaceuticals, Inc8$207
Astellas Pharma US Inc7$206
GSK10$202
Puma Biotechnology, Inc.9$197
Stemline Therapeutics Inc.8$196
Rigel Pharmaceuticals, Inc.11$188
Array Biopharma Inc13$177
Beigene USA, Inc.9$173
Gilead(2 entities)8$161
Acrotech Biopharma Inc.7$149
Pharmacyclics LLC, An Abbvie Company7$138
Takeda Pharmaceuticals U.S.A., Inc.6$133
Jazz Pharmaceuticals Inc.8$126
AVEO Pharmaceuticals, Inc.6$126
Pharmaessentia USA Corporation6$124
Boehringer Ingelheim4$123
Karyopharm Therapeutics Inc.6$123
Sanofi5$119
Dendreon Pharmaceuticals LLC5$117
Sanofi-aventis U.S. LLC1$100
Pharmacosmos Therapeutics Inc.5$97
Tersera Therapeutics LLC4$86
Geron Corporation4$85
Beone Medicines USA, Inc.4$82
ADC Therapeutics America, Inc.4$78
Sumitomo Pharma America, Inc.5$76
Genmab U.S., Inc.3$61
Amneal Pharmaceuticals LLC3$58
Servier Pharmaceuticals LLC3$53
Azurity Pharmaceuticals, Inc.3$52
EMD Serono, Inc.3$50
Deciphera Pharmaceuticals Inc.2$45
Morphosys, US Inc.3$43
Kyowa Kirin, Inc.2$34
Tempus AI, Inc1$28
Novocure Inc.1$27
Fennec Pharmaceuticals, Inc.1$23
Mirati Therapeutics, Inc.1$22
Avyxa Pharma, LLC1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,736 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$21,217
Medicare patients
126
Services billed
586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide40$464,310
RevlimidLenalidomide18$275,706
Lenalidomide16$246,589
EliquisApixaban39$31,631
Abiraterone Acetate15$12,549
Ondansetron OdtOndansetron157$3,641
Anastrozole87$2,510
Dexamethasone82$1,545
Lidocaine-PrilocaineLidocaine/Prilocaine102$1,298
Promethazine Hcl78$822
LoperamideLoperamide Hcl70$804
Letrozole18$489
Gabapentin14$373
Acyclovir36$277
Hydroxyurea14$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$206$464,31040 claims
Bristol Myers SquibbRevlimid$399$275,70618 claims
PfizerEliquis$809$31,63139 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$58$8613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Aiken

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →